How to Prepare Labels and Instructions for Medical Device Overseas Registration?

When registering a medical device overseas, labels and instructions for use (IFUs) are core technical documents that directly determine whether the product can be approved for the target market. Companies must first confirm whether the product falls under the target country's medical device regulatory scope, then select the registration pathway based on risk classification (e.g., ASEAN MDD, Saudi SFDA, Brazil ANVISA), and assess the reusability of existing NMPA/CE/FDA documentation, particularly whether ISO 13485 and MDSAP certificates can expedite review. Key preparation elements include: label components (symbols, language, warnings), IFU structure and clinical evidence references, and qualification confirmation of the local agent or authorized representative.

Introduction

This FAQ article addresses the preparation of labels and IFUs for medical device overseas registration. It covers the critical issues companies need to prioritize in real projects, including regulatory judgment logic, documentation and evidence, common mistakes, a preparation checklist, and expert perspectives.

Applicable Scenarios and Core Issues

Medical device companies planning to export to overseas markets (e.g., Southeast Asia, Middle East, Latin America, GHWP member states) must prepare labels and IFUs compliant with local regulations. These are key evidence in registration technical files; reviewers use them to judge product safety, effectiveness, and absence of misleading information. Regulatory requirements vary significantly: for example, ASEAN MDD requires labels in English and local languages, Saudi SFDA requires QR codes for traceability, and Brazil ANVISA mandates Portuguese versions of IFUs.

Companies often face three core questions: Can existing domestic or CE/FDA labels be used directly? What content must be added or removed? What evidence can be reused and what must be retested? Labels and IFUs are not only compliance documents but also affect post-market maintenance. Inconsistencies with registration files can lead to product detention or recall. Therefore, companies should integrate label and IFU preparation into the project plan from the registration initiation stage, with participation from regulatory, R&D, and quality departments.

Regulatory Judgment Logic

Step 1: Identify the target country and review its medical device regulations on labeling and IFUs. Most countries issue guidance documents (e.g., Saudi SFDA's 'Labeling Requirements for Medical Devices' or ASEAN's 'Medical Device Labeling Guidelines'). Step 2: Determine the depth of localization based on product risk level. Low-risk classes (e.g., Class I, IIa) may accept English labels with local language warnings; medium-to-high risk classes (IIb, III) usually require full translation and notarization or certification. Step 3: Assess reusability of existing documentation. If the product has CE MDR/IVDR or FDA 510(k) labels, check each difference against target country regulations—for example, whether the UDI-DI on CE labels must be converted to the target country format, or whether the 'Rx Only' symbol on FDA labels is allowed in other countries. ISO 13485 and MDSAP certificates can help demonstrate system compliance, but label content itself must still be independently reviewed. Step 4: Confirm the local agent's or authorized representative's label review capability. Some countries (e.g., Brazil, Saudi Arabia) require the local agent to co-sign or file labels. Companies should communicate timelines with the agent in advance to avoid delays. Step 5: Incorporate post-market maintenance plans into the label change mechanism. Changes to name, address, safety warnings, etc., may require prior regulatory approval (significant changes) or merely notification. It is advisable to establish a filing path for label changes during the preparation phase.

Documentation and Evidence

Required documentation includes three parts: current files, regulatory references, and gap analysis evidence. Current files include: product label physical images or design drafts, IFU documents (including source files), packaging design files, trademark registration certificates (if any), and product standards/technical requirements. Regulatory references include: original text or official guidelines of the target country's medical device labeling regulations, language translation requirements, and symbol standards (e.g., ISO 15223-1, EN 980, IEC 60417). Gap analysis evidence includes: a line-by-line comparison table between existing labels and target country requirements, completed and pending localization measures, translation accuracy certification (e.g., notarized translation company qualifications), and a label content consistency statement signed by the company confirming that labels conform to registration files.

For multi-country registration, prepare a core label template with variable fields (e.g., local agent address, local language warnings, registration number). Then generate independent localized versions for each target country. Keep modification records and version numbers for all label versions to facilitate reviewer traceability. Evidence chain should also include: label printing sample photos or proofing confirmations, and source reliability statements for IFUs (e.g., clinical usage data, user manual compilation process). If usability engineering reports are available, cite design of warnings for misuse.

Common Mistakes

• Ignoring target country language requirements and submitting only English labels, leading to rejection.
• Using symbols that do not comply with ISO 15223-1 or local symbol specifications, such as prohibition symbols not scaled to standard dimensions.
• IFU content inconsistent with registration technical files, e.g., errors in model/size descriptions or omission of contraindications.
• Failure to consider local cultural differences in warning phrasing, leading to misunderstanding or offensiveness.
• Manufacturer name and address on labels not matching those on the registration certificate, or omitting local agent information.
• IFUs missing necessary information such as shelf life, maintenance methods, or calibration intervals.
• Unauthorized changes to CE or FDA approved labels to adapt to new markets without assessing impact on original approvals.
• No historical records or approval records of label changes retained, making it impossible to provide evidence during post-market surveillance.

Preparation Checklist

1. Establish a target country label regulatory database, collecting the latest regulations and guidelines.
2. Create a label and IFU gap analysis matrix—list all regulatory requirements and compare line by line with existing documentation.
3. Select a language translation supplier and require a translation qualification statement.
4. Arrange for the local agent or authorized representative to pre-review label drafts.
5. Verify that all symbols and abbreviations on labels comply with target country regulations (e.g., restrictions on UL, CE, FDA symbols).
6. Confirm IFU structure includes: intended use, contraindications, warnings, precautions, adverse effects, instructions for use, storage and maintenance, etc.
7. Prepare a statement of consistency between labels/IFUs and the quality management system (e.g., ISO 13485).
8. Establish a document control number and version history for each target country version.
9. Plan a label change management process: define which changes require prior notification to the agent or re-registration.
10. If the product has multiple models, ensure labels and IFUs for each model are completed.

AIMEILI's Perspective

Companies most commonly misjudge that CE or FDA labels can be directly transferred overseas, ignoring local language, symbol, and agent information requirements. In the early project phase, prioritize regulatory gap analysis, establish a reusable core label template, and sign contracts with local agents early, involving them deeply in label review. The following documentation can be reused: ISO 15223-1 symbol set, CE marking usage guidelines, and warning designs from usability engineering. Items that must be localized: language translation, locally mandated items (e.g., indications wording, safety expiration date representation), and agent information. Special attention is needed for GHWP member state registration: many countries accept CE documentation as a basis, but labels and IFUs must additionally comply with the country's own 'Medical Device Instructions and Labeling Regulations.' We recommend treating labels and IFUs as independent technical documents, not appendices to registration files. Furthermore, in multi-country registration, certificate control and change/continuation label version management are critical—a small modification could invalidate all certificates. We suggest establishing a dedicated label specialist within the regulatory department or engaging a consultancy to manage global label versions.

Frequently Asked Questions

Do label translations need notarization?

Requirements vary by target country. For example, Brazil INMETRO requires that medical device labels be translated and notarized by a translator registered in Brazil; ASEAN countries generally only require a qualification statement from the translation company. Always confirm the specific notarization requirements of the target country to avoid rejection due to missing notarization.

If a product has CE labels, can the CE symbol be used directly in non-CE countries?

No. The CE mark only indicates compliance with EU regulations; non-EU countries do not recognize its conformity, and some countries prohibit the use of the CE symbol on labels to avoid misleading users. Remove the CE symbol and replace it with the target country's accepted conformity mark (e.g., local registration number or local compliance mark).

Do contraindications in the IFU need to be listed separately by country?

Yes. Different countries may have different contraindication requirements for the same product based on local epidemiology, ethnic differences, and clinical practices. For example, drug-eluting stents may have different antiplatelet therapy duration recommendations in Asia versus Europe/America, directly affecting contraindication descriptions. Companies should adjust IFU content based on clinical data or local guidelines of the target market.